Hikal Q1 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 1
Fundraise
Yes
Order
N/A
Capex
Yes
3 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 3- Revenue target of around ₹3,000 crore expected in a few years; not within the next two years but slightly beyond that (Sameer Hiremath).
- Existing gross block can achieve ₹2,400-2,500 crore with improved utilization and better product mix; new capacity to add ₹500-600 crore (Sameer Hiremath).
- Volumes declined in Q1 FY24 due to inventory destocking; volume uptick expected from Q3 FY24 onwards (Sameer Hiremath).
- Peak utilization of new capacity will take 3-4 years to achieve (Sameer Hiremath).
- Topline of ₹3,500 crore expected once optimal capacities are reached, which is 2-3 years post commissioning (Sameer Hiremath).
- Improvement expected in volumes and margins from H2 FY24 onwards; sequential quarter-on-quarter recovery anticipated (Sameer Hiremath).
- Medium to long-term growth outlook positive; demand recovery expected in pharma and crop protection segments (Sameer Hiremath, Manoj Mehrotra).
See what Hikal management said on margin guidance — free account, 30 seconds.
Fundraise plans
Yes- Hikal Limited does not plan any fresh equity fundraising as per the latest call.
- For the current year, the company plans a CAPEX of approximately ₹200 crore.
- The funding for this CAPEX is expected to be 50% from internal accruals and 50% through borrowings (debt).
- The company already has outstanding term loans of ₹550 crore and working capital borrowings of ₹240 crore.
- Debt repayments have already commenced and will continue over the next few years.
- Kuldeep Jain (CFO) stated they are comfortable with current debt levels.
- Long-term total debt levels are expected to remain roughly stable by March 2024.
- Cost of funds for the long-term borrowings is approximately 8.5%.
See what Hikal management said on order book — free account, 30 seconds.
Capex plans
Yes- Current capital work-in-progress (WIP) as of June 30, 2023 is about ₹400-460 crores, largely for recently completed projects.
- Additional CAPEX of ₹100-120 crores is expected over the next three quarters to fully commission new capacities.
- New multipurpose animal health plant at Panoli is built and undergoing commissioning with validation batches expected in the next few quarters.
- The new capacity ramp-up will add around ₹500-600 crores in revenue potential beyond the existing asset base.
- Company plans about ₹200 crore investment in the current year, funded roughly 50% by internal accruals and 50% by debt.
- Debt for CAPEX is manageable; no new long-term loans borrowed in recent quarter; debt-equity ratio is well within norms.
- Commissioning and revenue contribution from new assets expected mainly from Q3/Q4 FY24 onwards.
- Strategic focus on enhancing manufacturing, supply chain, and ESG integration through "Project Pinnacle" for sustainable growth.
Track Hikal — get its next earnings analysis in your feed
Margin guidance
Category 1- Hikal expects a medium to long-term sustainable growth outlook despite short-term volatility, with demand uptick anticipated from Q3/Q4 FY24 onwards.
- Operating margins are targeted to improve from current 13%-14% levels back to historical 18%-19% within a few years for existing assets; new projects aim for EBITDA margins around 22%-24%.
- The company’s aspirational revenue target is around Rs. 3,000 crore in a few years, with current assets contributing Rs. 2,400-2,500 crore and new capacity adding Rs. 500-600 crore.
- Longer-term targets are significantly higher, with confidence in exceeding revenue of Rs. 6,000 crore by 2030; failure to do so would cause disappointment.
- EBITDA margins for the new projects target approximately 24%-25%, with a blended margin expected around 20%-23%.
- Enhanced operational efficiencies, new product mix, and commissioned capacities underpin growth and margin improvements over the next 3-5 years.
Order book
- The transcript does not provide specific details or figures regarding the current or expected order book or pending orders for Hikal Limited.
- However, the company mentions a strong pipeline of products under evaluation and implementation for global multinational clients.
- There is also mention of onboarding several new customers due to increased marketing efforts.
- The company highlights ongoing positive discussions with global innovators and opportunities for setting up dedicated capacities for clients.
- Overall, while exact order book numbers are not disclosed, the company indicates healthy demand prospects, ongoing client engagements, and a favorable outlook for order inflow.
How does Hikal rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Hikal rank in Pharmaceuticals & Biotechnology?
Compare Hikal against every Pharmaceuticals & Biotechnology company (Q1 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Hikal's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- IOL Chemicals (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharma. (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
- Strides Pharma (Q1 FY27)
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…